Susan O'Brien

发表

Full Code (Resuscitate)

Susan O'Brien, 2019 .

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Susan O'Brien, Weiqiang Zhao, Gautam Borthakur, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Susan O'Brien, Jorge Cortes, John Nicoll, 2006, The New England journal of medicine.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

Susan O'Brien, Nitin Jain, Z. Estrov, 2015, Blood.

Chronic myelogenous leukemia: A review and update of therapeutic strategies

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2003, Cancer.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Susan O'Brien, Koji Sasaki, Naveen Pemmaraju, 2018, The Lancet. Haematology.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Steven M Kornblau, Susan O'Brien, Jorge Cortes, 2004, Blood.

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease

Rosario Giustolisi, Marco Montillo, Susan O'Brien, 2002, Cancer.

Chronic lymphocytic leukemia

Susan O'Brien, J. Cortes, S. O'brien, 2011 .

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.

Susan O'Brien, Jorge Cortes, Moshe Talpaz, 2007, Blood.

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

Susan O'Brien, Jason Gotlib, Moshe Talpaz, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, 2010, Modern Pathology.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Juthamas Sukbuntherng, Susan O'Brien, Jeffrey A Jones, 2013, The New England journal of medicine.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Mark Brandt, Susan O'Brien, B Nebiyou Bekele, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Arturo Molina, Susan O'Brien, Nyla Heerema, 2010, Blood.

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Susan O'Brien, Jorge Cortes, E. Estey, 2006, Cancer.

Design, development, and validation of a high‐throughput drug‐screening assay for targeting of human leukemia

Steven M Kornblau, Wadih Arap, Renata Pasqualini, 2014, Cancer.

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Susan O'Brien, Alice Lynn, Lynne V Abruzzo, 2008, Blood.

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Cancer.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Susan O'Brien, Gautam Borthakur, Marina Konopleva, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Susan O'Brien, Jorge Cortes, Rajyalakshmi Luthra, 2005, Clinical Cancer Research.

Survival benefit with imatinib mesylate therapy in patients with accelerated‐phase chronic myelogenous leukemia—Comparison with historic experience

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2005, Cancer.

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.

Naveen Garg, Dominik Wodarz, Xuelin Huang, 2017, JCI insight.

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Kim-Anh Do, Susan O'Brien, Jorge Cortes, 2007, Blood.

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Very long‐term follow‐up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

Susan O'Brien, Jorge Cortes, H. Kantarjian, 2012, Cancer.

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Susan O'Brien, Jorge Cortes, H. Kantarjian, 2013, Clinical lymphoma, myeloma & leukemia.

Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Susan O'Brien, Samir Parekh, Meir Wetzler, 2013, Clinical lymphoma, myeloma & leukemia.

NCCN Task Force Report: Oral chemotherapy.

Susan O'Brien, Saul N Weingart, Peter B Bach, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

Susan O'Brien, Guillermo Garcia-Manero, Elias Jabbour, 2011 .

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients

Susan O'Brien, Lynne V Abruzzo, Michael J Keating, 2008, British journal of haematology.